Ingersoll Rand announced on January 5 2026 that it had agreed to acquire Scinomix, Inc., a U.S. developer of laboratory automation solutions that include labeling, handling, barcode scanning and capping systems. The deal adds Scinomix’s technology to Ingersoll Rand’s Precision and Science Technologies segment, broadening the company’s end‑to‑end offerings for clinical, pharmaceutical, biotechnology, forensic, agricultural and genetic testing laboratories.
Scinomix, founded in 2013, has grown to a 26‑person, unfunded company that serves a diverse set of life‑science customers. Its products are designed to streamline sample management and improve traceability, and the company has positioned itself as a key player in the growing market for scalable, configurable laboratory automation.
The transaction was priced at a pre‑synergy purchase multiple of roughly 10× 2025 Adjusted EBITDA, but the exact monetary value was not disclosed. The multiple indicates that Ingersoll Rand values Scinomix at a level consistent with its recent acquisitions in the life‑sciences space, such as the 2024 purchase of ILC Dover.
Ingersoll Rand’s recent financial performance underscores the strategic fit of the acquisition. In Q4 2024 the company generated $1.899 billion in revenue and $532 million in adjusted EBITDA, a 28.0% margin. In Q1 2025 revenue fell to $1.717 billion and adjusted EBITDA to $460 million, a 26.8% margin. The company also spent $496.1 million on acquisitions in 2025, reflecting a continued focus on bolt‑on growth.
The acquisition is part of Ingersoll Rand’s broader strategy to deepen its life‑sciences platform. By adding Scinomix’s automation technologies, the company can offer a more comprehensive, end‑to‑end solution that enhances efficiency, accuracy and traceability for laboratory customers. The move builds on the 2024 ILC Dover acquisition and positions Ingersoll Rand to capture a larger share of the high‑growth life‑sciences market.
Vicente Reynal, Chairman and CEO, said the deal “expands our portfolio of innovative solutions and opens new opportunities with the acquisition of Scinomix. Their expertise in automation technologies within life sciences strategically complements existing capabilities at Ingersoll Rand, enabling us to better serve our customers.”
The integration of Scinomix into the Precision and Science Technologies segment is expected to strengthen Ingersoll Rand’s competitive position across a broad spectrum of laboratory environments, from clinical diagnostics to agricultural testing. While specific synergy targets and integration timelines have not been disclosed, the acquisition is anticipated to accelerate the company’s ability to deliver scalable, configurable automation solutions to a growing customer base.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.